IDH2 and neoplasm: Furthermore, mutations in IDH genes, particularly IDH2, have been shown to result in the production of oncometabolites, such as 2-hydroxyglutarate, which can disrupt cellular signaling pathways and epigenetic regulation, thereby contributing to tumor initiation and progression [35,36].